Man Group plc Makes New Investment in HealthEquity, Inc. $HQY

Man Group plc bought a new stake in HealthEquity, Inc. (NASDAQ:HQY) during the second quarter, Holdings Channel reports. The institutional investor bought 67,560 shares of the company’s stock, valued at approximately $6,102,000.

Other institutional investors and hedge funds have also recently bought and sold shares of the company. BlackRock Inc. acquired a new position in HealthEquity in the second quarter valued at $1,018,621,000. William Blair Investment Management LLC acquired a new stake in shares of HealthEquity during the fourth quarter worth about $169,956,000. Jupiter Topco LLC purchased a new position in shares of HealthEquity during the second quarter worth about $78,847,000. Wasatch Advisors LP grew its holdings in shares of HealthEquity by 10.5% during the second quarter. Wasatch Advisors LP now owns 7,960,735 shares of the company’s stock worth $719,014,000 after buying an additional 757,801 shares during the last quarter. Finally, Norges Bank acquired a new position in HealthEquity in the 4th quarter valued at about $66,927,000. Hedge funds and other institutional investors own 99.55% of the company’s stock.

Key HealthEquity News

Here are the key news stories impacting HealthEquity this week:

• Positive Sentiment: HealthEquity exceeded expectations with adjusted earnings of $1.24 per share versus the $1.19 consensus, while revenue reached $350.7 million, slightly above estimates. Revenue increased 95.5% year over year. HealthEquity Q2 Earnings and Revenues Top Estimates
• Positive Sentiment: Profitability improved, with net income rising 10% to $65.6 million and net margin expanding to 19% from 18%. Adjusted EBITDA grew 11% to $167 million, while its margin increased to 48% from 46%. HealthEquity Second-Quarter Financial Results
• Positive Sentiment: Management raised fiscal 2027 adjusted EPS guidance to $4.66–$4.73, above the $4.56 analyst consensus. Record HSA assets of $37.9 billion provide additional support for the company’s long-term growth outlook. HealthEquity Raises Fiscal 2027 Guidance
• Positive Sentiment: BTIG Research reaffirmed its “buy” rating and raised its price target to $115. Another analysis indicated that HQY could be approximately 19% undervalued after the guidance increase, reinforcing the bullish interpretation of the earnings update. BTIG Research Rating HealthEquity Could Be Undervalued
• Neutral Sentiment: Fiscal 2027 revenue guidance of approximately $1.4 billion was broadly in line with expectations, so the guidance improvement was driven mainly by stronger anticipated earnings and margins.
• Negative Sentiment: Director Adrian T. Dillon sold 7,632 shares valued at approximately $798,000, reducing his position by 10.9%. The sale was executed under a pre-arranged Rule 10b5-1 plan, which reduces its negative signaling value but could still attract investor attention. HealthEquity Director Stock Sale
• Negative Sentiment: HQY trades at a premium valuation of roughly 35 times earnings. After the recent advance toward its 52-week high, some investors may lock in gains, potentially tempering the stock’s reaction to otherwise favorable fundamentals.

Wall Street Analyst Weigh In

Several equities research analysts have recently commented on HQY shares. Royal Bank Of Canada upped their price target on HealthEquity from $100.00 to $108.00 and gave the stock an “outperform” rating in a research note on Wednesday, June 3rd. KeyCorp restated an “overweight” rating on shares of HealthEquity in a research report on Tuesday, May 26th. Telsey Advisory Group set a $111.00 target price on shares of HealthEquity in a report on Friday. Weiss Ratings upgraded shares of HealthEquity from a “hold (c)” rating to a “hold (c+)” rating in a research note on Friday, June 5th. Finally, Citigroup reiterated a “market outperform” rating on shares of HealthEquity in a research note on Friday. Eleven equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat.com, HealthEquity presently has a consensus rating of “Moderate Buy” and a consensus price target of $110.93.

HealthEquity Stock Up 3.2%

Shares of NASDAQ HQY opened at $96.37 on Friday. HealthEquity, Inc. has a 12-month low of $72.76 and a 12-month high of $107.62. The company has a market capitalization of $8.06 billion, a PE ratio of 34.79, a price-to-earnings-growth ratio of 1.62 and a beta of 0.21. The company has a debt-to-equity ratio of 0.47, a current ratio of 2.99 and a quick ratio of 3.44. The firm’s 50-day moving average is $98.16 and its two-hundred day moving average is $87.87.

HealthEquity (NASDAQ:HQY) last released its quarterly earnings results on Thursday, August 27th. The company reported $1.24 earnings per share for the quarter, topping the consensus estimate of $1.19 by $0.05. The company had revenue of $350.73 million during the quarter, compared to the consensus estimate of $349.22 million. HealthEquity had a return on equity of 15.33% and a net margin of 17.36%.The business’s revenue was up 95.5% compared to the same quarter last year. HealthEquity has set its FY 2027 guidance at 4.660-4.730 EPS. Equities analysts anticipate that HealthEquity, Inc. will post 3.92 EPS for the current fiscal year.

Insider Buying and Selling at HealthEquity

In other news, Director Adrian T. Dillon sold 7,632 shares of the company’s stock in a transaction dated Tuesday, August 25th. The shares were sold at an average price of $104.61, for a total transaction of $798,383.52. Following the completion of the transaction, the director owned 62,395 shares of the company’s stock, valued at $6,527,140.95. This represents a 10.90% decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, EVP Michael Henry Fiore sold 2,470 shares of the company’s stock in a transaction that occurred on Thursday, July 2nd. The stock was sold at an average price of $95.00, for a total transaction of $234,650.00. Following the transaction, the executive vice president directly owned 56,643 shares of the company’s stock, valued at $5,381,085. This trade represents a 4.18% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold 12,456 shares of company stock valued at $1,256,664 over the last quarter. Insiders own 1.60% of the company’s stock.

About HealthEquity

HealthEquity, Inc (NASDAQ: HQY) is a leading administrator of consumer-directed health accounts and related benefit solutions in the United States. Founded in 2002 and headquartered in Draper, Utah, the company specializes in health savings accounts (HSAs) and offers complementary services such as flexible spending accounts (FSAs), health reimbursement arrangements (HRAs), COBRA administration and commuter benefits. Through its technology-driven platform, HealthEquity enables employers, health plans and individuals to streamline account management, improve cost transparency and encourage more informed healthcare spending.

Serving millions of members across all 50 states, HealthEquity leverages an open-architecture ecosystem that integrates with health plans, payroll providers and financial institutions.